Another study in lung cancer compared the efficacy of crizotinib (ALK inhibitor) against standard-of-care agents, Docetaxel or Pemetrexed, in an EML4-ALK mouse model and Phase III human clinical trials. This evidence concerns the gene ALK and lung carcinoma.